Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

The Immune Response to Autologous Bacteroides in Ankylosing Spondylitis Is Characterized by Reduced Interleukin 10 Production

SIMON M. STEBBINGS, CORINDA TAYLOR, GERALD W. TANNOCK, MARGARET A. BAIRD and JOHN HIGHTON
The Journal of Rheumatology April 2009, 36 (4) 797-800; DOI: https://doi.org/10.3899/jrheum.080964
SIMON M. STEBBINGS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: simon.stebbings{at}otago.ac.nz
CORINDA TAYLOR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GERALD W. TANNOCK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARGARET A. BAIRD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOHN HIGHTON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Abstract

Objective. Ileocolitis is a recognized feature of ankylosing spondylitis (AS) and is likely to play a role in the pathogenesis of AS, in conjunction with the normal intestinal microbiota. In order to investigate the host immune response in AS, we measured cytokines in tissue culture following exposure of peripheral blood mononuclear cells (PBMC) to autologous colonic bacteria.

Methods. Twenty-one patients with AS and 21 matched controls were recruited. Subjects in the AS group were assessed clinically. Bacteroides species belonging to the B. fragilis group were selectively cultured from stool samples and paired with blood samples from each participant. Ten cultures of autologous Bacteroides were randomly selected from cultures grown from the fecal specimens of each of the 21 patients with AS and 21 controls. These were then tested for reactivity with PBMC and the cytokines produced by proliferating lymphocytes [interleukin 10 (IL-10), IL-17, interferon-γ, tumor necrosis factor-α] were measured in cell culture supernatants. Differences between groups were analyzed using censored normal regression analysis.

Results. The patients with AS had severe active AS with Bath AS Disease Activity Index 5.5 (± 1.6) and C-reactive protein (mg/l) 13.8 (± 12.2) (mean ± standard deviation). IL-10 concentrations in ex vivo assay supernatants were lower in the AS group compared with controls (p = 0.047). There were no statistically significant differences between the groups for other cytokines.

Conclusion. In AS, reduced IL-10 production in response to stimulation with autologous Bacteroides cultures may represent a mechanism by which intestinal inflammation develops and persists, a situation analogous to inflammatory bowel disease.

  • ANKYLOSING SPONDYLITIS
  • INTERLEUKIN 10
  • BACTEROIDES SPECIES
  • FECAL MICROBIOTA

In ankylosing spondylitis (AS) there is evidence that an environmental trigger, originating in the gastrointestinal tract, is an etiological factor. This has been demonstrated in an animal model, where rats transgenic for human HLA-B27 have been shown to develop a disease characterized by inflammation of the spine and joints and colitis1. However, if these rats are derived under germ-free conditions they remain healthy. Subsequent colonization of the gut with normal commensals, particularly Bacteroides vulgatus, leads to the development of disease in these rats2. These observations indicate that interactions between a dysfunctional immune system and the bowel microbiota are fundamental aspects of the pathogenesis of AS. Further, in human populations, a strong association with Crohn’s disease3 is well established and ileocolitis has been observed in two-thirds of patients with AS4.

We have shown previously that the proportions of the major bacterial phylotypes comprising the fecal microbiota did not differ between subjects with AS and healthy controls5. Moreover, populations of B. vulgatus, a bacterium shown to promote colitis in HLA-B27 transgenic rats6, did not differ in size between patients with AS and controls. We therefore postulated that the nature of the host immune response to autologous bowel bacteria may be of greater importance than the presence or absence of particular bacterial species. To investigate this, we measured the cytokine profile produced by peripheral blood mononuclear cells (PBMC) from patients with AS when exposed to the cells of autologous Bacteroides.

MATERIALS AND METHODS

Ethical approval was obtained from the Lower South Regional Ethics Committee.

Twenty-one patients fulfilling the Modified New York Criteria for definite AS7 and 21 age- and sex-matched controls were recruited to the study. Patients with AS and controls were excluded from the study if they were pregnant, or had a current infection, a history of inflammatory bowel disease (IBD) or malignancy. In addition, controls were excluded if they had a history of arthritis, uveitis, or psoriasis.

All patients were assessed clinically using the following instruments identified as core measures. Disease activity and severity was assessed using the Bath AS Indices: Disease Activity Index, BASDAI; Functional Index, BASFI; Global Assessment, BAS-G; and Metrology Index, BASMI8. The C-reactive protein (CRP), 44-joint peripheral tender and swollen joint count, and Maastricht AS Enthesitis Score (MASES) were also recorded9. Treatment with nonsteroidal antiinflammatory drugs (NSAID) and disease modifying antirheumatic drugs (DMARD) was recorded.

Patients and controls were assessed on a single occasion and provided a single blood sample and fecal sample within 1 week of the clinical assessment.

Bacteroides cultures

Fecal samples were collected from patients with AS and controls and cultured within 2 h of collection. All subsequent manipulations were carried out in an anaerobic glovebox. Homogenates (10% w/v) were prepared and diluted in 10-fold steps to 1 × 10−8 using brain-heart infusion broth supplemented with vitamin K and hemin (BHIS)10. One hundred-milliliter aliquots of dilutions were spread on plates of Bacteroides-Bile-Aesculin agar (which selects for members of the B. fragilis group, including B. vulgatus). The plates were incubated anaerobically for 2 days at 37°C. Ten bacterial colonies were picked from BHIS plates showing discrete colonies. Culture media used in the study had been prereduced before use for 24 h in an anaerobic glovebox. BHIS broth cultures of the 10 pure cultures obtained from each of the subjects were used separately to obtain Bacteroides cells by centrifugation. The cells were washed twice in sterile 0.85% sodium chloride solution and the bacterial suspensions were standardized spectrophotometrically to 1 × 109 CFU per ml. The bacterial cells were heat-killed (80°C, 30 min) and the suspensions were stored at −80°C until use11.

Preparation and use of PBMC

Twenty-milliliter volumes of heparinized blood were obtained from patients with AS and controls. PBMC were purified from the blood by centrifugation through a Ficoll-Hypaque gradient (Amersham Biosciences, Little Chalfont, Buckinghamshire, UK). The cells were cultured at 37°C in a modified atmosphere incubator (5% carbon dioxide) in flat-bottomed microtiter plates using Iscove’s modified Dulbecco medium containing insulin, transferrin, bovine serum albumin, penicillin/streptomycin, and 2-ME. Triplicate cultures of PBMC from each patient at 2 × 105 per well were separately exposed to each of their 10 autologous Bacteroides suspensions at 2 × 106 cells per well for 5 days. Negative controls contained PBMC and culture medium, whereas positive controls contained PBMC and staphylococcal enterotoxin A (SEA; 50 ng per well). Culture supernatants were subsequently used to measure the concentrations of interleukin 10 (IL-10), IL-1ß, IL-17, interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-α), using BioPlex Suspension Array methodology (Bio-Rad Laboratories, Hercules, CA, USA).

Statistical analysis

Mean values for the 10 different Bacteroides colonies selected from each individual and resultant cytokine profiles were analyzed using censored normal regression analysis, where allowance was made for censored values outside the limits of detection of the assay. No adjustments have been made for multiple testing.

RESULTS

The patient group was characterized by severe active AS, mean duration 18.4 years (Table 1).

View this table:
  • View inline
  • View popup
Table 1.

Clinical and demographic characteristics of the AS subjects and controls.

All patients with AS were HLA-B27-positive with radiographic evidence of sacroiliitis (Grade ≥ 2 bilateral or 3–4 unilaterally). It was noted that 19 of the 21 patients would qualify for treatment with a biologic agent using Australian criteria. None of the subjects were receiving such treatment, as it is unavailable for this indication in New Zealand.

Table 2 shows cytokine production following exposure of PBMC to autologous Bacteroides cells and to SEA 50 ng as positive control.

View this table:
  • View inline
  • View popup
Table 2.

Cytokine levels (pg/ml) measured following peripheral blood mononuclear cell (PBMC) stimulation with autologous Bacteroides cells and Staphylococcal enterotoxin (control stimulus).

Significantly lower levels of IL-10 were produced following stimulation with autologous Bacteroides in the AS group. In contrast, both groups responded similarly to SEA stimulation. No significant difference between AS and control groups was noted with any of the other cytokines. There was no correlation between any clinical variable and cytokine levels.

DISCUSSION

We defined a group of patients with severe AS naive to biologic therapies. In comparison to healthy controls, we observed attenuated IL-10 production by the PBMC of patients with AS when exposed to autologous isolates of Bacteroides cells. This finding is of interest since IL-10 has been shown to play an important role in mucosal tolerance in IBD, a condition acknowledged to have both genetic and histopathological commonality with AS. This attenuation could not be attributed to a defect in IL-10 production by PBMC from patients with AS, as no significant difference was noted in IL-10 production following stimulation with superantigen (SEA) between subjects and controls, and no difference was noted in production of any other measured cytokines following Bacteroides stimulation.

Although there are in excess of 400 bacterial species in the human colon, Bacteroides species constitute up to 30% of the fecal microbiota12. Tolerance to this huge antigenic load is a vital function of the mucosal immune system in the intestinal tract.

In AS, evidence that the intestinal microbiota act as an antigenic stimulant to both colonic inflammation and arthritis is largely confined to animal models, specifically the HLA-B27 transgenic rat model. Differential colonization of gnotobiotic animals has shown that B. vulgatus induces the strongest proinflammatory response, significantly greater than that seen with E. coli2,6. It was for this reason that we chose members of the B. fragilis group (which includes B. vulgatus) as the source of antigenic stimulation in our study.

There is substantial evidence that the intestinal tract is in a constant state of controlled inflammation. Loss of this control is an important mechanism in the development of IBD13. Animal models reveal the importance of an intact immune system for this homeostatic process since cytokine gene deletions and altered T cell subsets in murine models result in the development of IBD-like syndromes14,15.

IL-10 plays a critical role in such mucosal immune regulation in the gut, and this is demonstrated by observations in mouse models. Mice deficient for the IL-10 gene develop an enterocolitis. Local mucosal delivery of recombinant IL-10 by modified Lactococcus lactis seems effective in ameliorating colitis in IL-10-deficient mice13. The development of colitis is dependent on the presence of bowel bacteria, since IL-10-deficient mice do not develop colonic inflammation under germ-free conditions16.

In humans, evidence of loss of tolerance to resident intestinal microbiota in IBD was demonstrated by Duchmann, et al17. In their study, PBMC and lamina propria cells from IBD patients with active colitis, colitis in remission, and normal controls were exposed to both autologous and heterologous colonic bacteria. PBMC of patients with active IBD strongly proliferated in response to autologous bacteria. PBMC of controls and those in remission did not, but did proliferate in response to heterologous bacteria. Further, although the activated PBMC produced high levels of IFN-γ and IL-12, there was no corresponding increase in IL-10.

The strong association between AS and Crohn’s disease3,18 and the consistent demonstration of ileocolitis in patients with AS have been noted earlier. In this context, the finding of a deficient IL-10 response to autologous Bacteroides in AS is intriguing.

Although we have demonstrated significantly lower IL-10 production in AS following stimulation of PBMC with autologous bacterial cultures, we can only speculate on the mechanism for this. Further, our cohort was selected such that all participants with AS had severe, active AS. This did not allow us to demonstrate any correlation between reduced IL-10 levels and disease activity, although further studies examining this would be of interest. A previous study investigated PBMC cytokine production in AS in response to a standard phytohemagglutinin stimulation, and correlated this with disease activity as measured by BASDAI. This demonstrated a linear increase in levels of IL-1ß and TNF-α with increasing BASDAI, and a similar linear decline in IL-10 production in association with disease activity (p < 0.01)19.

One notable feature of IL-10 is its ability to induce regulatory T cell (Treg) development. These suppressive cells are termed adaptive Treg and they have been further characterized as Tr1 and Th3 cells20,21. These cells mediate their action predominantly through the production of antiinflammatory cytokines, IL-10 in the case of Tr1 cells and transforming growth factor-ß in the case of Th3 cells. Such cells vary in number in active IBD with a contraction of the peripheral blood Treg pool and a moderate expansion in the inflamed intestinal mucosa. Investigation of the number of Treg cells and their functional capacity in the gut mucosa, peripheral circulation, and synovial membrane would be worthy of consideration given our results.

We have shown reduced IL-10 production following PBMC stimulation with autologous Bacteroides species in patients with severe AS, compared with healthy controls. We suggest that this may be an important mechanism in the pathogenesis and persistence of inflammation in this condition. We further postulate that a loss of tolerance to numerically significant constituents of the intestinal microbiota may be mediated by this reduced immunoregulatory cytokine secretion. Extrapolation from current knowledge in IBD suggests that this may reflect reduced proliferation and activity of the adaptive Treg cell responses in AS.

Acknowledgments

We thank Debra McNamara for her invaluable contribution to this project, and Peter Herbison, Department of Social and Preventive Medicine, University of Otago, for statistical advice.

Footnotes

  • Supported by the University of Otago through a Faculty Trust Research Award.

    • Accepted for publication November 30, 2008.

REFERENCES

  1. 1.↵
    1. Hammer RE,
    2. Maika SD,
    3. Richardson JA,
    4. Tang JP,
    5. Taurog JD
    . Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 1990;63:1099–112.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Rath HC,
    2. Herfarth HH,
    3. Ikeda JS,
    4. et al
    . Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta 2 microglobulin transgenic rats. J Clin Invest 1996;98:945–53.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Haslock I
    . Arthritis and Crohn’s disease. A family study. Ann Rheum Dis 1973;32:479–86.
    OpenUrlFREE Full Text
  4. 4.↵
    1. Mielants H,
    2. Veys EM,
    3. De Vos M,
    4. et al
    . The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol 1995;22:2266–72.
    OpenUrlPubMed
  5. 5.↵
    1. Stebbings S,
    2. Munro K,
    3. Simon MA,
    4. et al
    . Comparison of the faecal microflora of patients with ankylosing spondylitis and controls using molecular methods of analysis. Rheumatology Oxford 2002;41:1395–401.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Rath HC,
    2. Wilson KH,
    3. Sartor RB
    . Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli. Infect Immun 1999;67:2969–74.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. van der Linden S,
    2. Valkenburg HA,
    3. Cats A
    . Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. van der Heijde D,
    2. van der Linden S,
    3. Bellamy N,
    4. Calin A,
    5. Dougados M,
    6. Khan MA
    . Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV. J Rheumatol 1999;26:945–7.
    OpenUrlPubMed
  9. 9.↵
    1. Heuft-Dorenbosch L,
    2. Spoorenberg A,
    3. van Tubergen A,
    4. et al
    . Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127–32.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Holdeman LV,
    2. Cato EP,
    3. Moore WEC
    . Anaerobe laboratory manual. Blacksburg: VPI Anaerobe Laboratory, Virginia Polytechnic Institute and State University; 1973.
  11. 11.↵
    1. Kimura K,
    2. McCartney AL,
    3. McConnell MA,
    4. Tannock GW
    . Analysis of fecal populations of bifidobacteria and lactobacilli and investigation of the immunological responses of their human hosts to the predominant strains. Appl Environ Microbiol 1997;63:3394–8.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Gibson GR,
    2. Roberfroid MB
    . Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995;125:1401–12.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Huibregtse IL,
    2. van Lent AU,
    3. van Deventer SJ
    . Immunopathogenesis of IBD: insufficient suppressor function in the gut? Gut 2007;56:584–92.
    OpenUrlFREE Full Text
  14. 14.↵
    1. Powrie F,
    2. Leach MW
    . Genetic and spontaneous models of inflammatory bowel disease in rodents: evidence for abnormalities in mucosal immune regulation. Ther Immunol 1995;2:115–23.
    OpenUrlPubMed
  15. 15.↵
    1. Elson CO,
    2. Sartor RB,
    3. Tennyson GS,
    4. Riddell RH
    . Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344–67.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Strober W,
    2. Fuss IJ,
    3. Blumberg RS
    . The immunology of mucosal models of inflammation. Annu Rev Immunol 2002;20:495–549.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Duchmann R,
    2. Kaiser I,
    3. Hermann E,
    4. Mayet W,
    5. Ewe K,
    6. Meyer zum Buschenfelde KH
    . Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448–55.
    OpenUrlPubMed
  18. 18.↵
    1. Haslock I
    . The arthritis associated with Crohn’s disease: a family study. Rheumatol Rehabil 1973;12:93
    OpenUrlPubMed
  19. 19.↵
    1. Chou CT,
    2. Huo AP,
    3. Chang HN,
    4. Tsai CY,
    5. Chen WS,
    6. Wang HP
    . Cytokine production from peripheral blood mononuclear cells in patients with ankylosing spondylitis and their first-degree relatives. Arch Med Res 2007;38:190–5.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Wing K,
    2. Fehervari Z,
    3. Sakaguchi S
    . Emerging possibilities in the development and function of regulatory T cells. Int Immunol 2006;18:991–1000.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Coombes JL,
    2. Maloy KJ
    . Control of intestinal homeostasis by regulatory T cells and dendritic cells. Semin Immunol 2007;19:116–26.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 36, Issue 4
1 Apr 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Immune Response to Autologous Bacteroides in Ankylosing Spondylitis Is Characterized by Reduced Interleukin 10 Production
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Immune Response to Autologous Bacteroides in Ankylosing Spondylitis Is Characterized by Reduced Interleukin 10 Production
SIMON M. STEBBINGS, CORINDA TAYLOR, GERALD W. TANNOCK, MARGARET A. BAIRD, JOHN HIGHTON
The Journal of Rheumatology Apr 2009, 36 (4) 797-800; DOI: 10.3899/jrheum.080964

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
The Immune Response to Autologous Bacteroides in Ankylosing Spondylitis Is Characterized by Reduced Interleukin 10 Production
SIMON M. STEBBINGS, CORINDA TAYLOR, GERALD W. TANNOCK, MARGARET A. BAIRD, JOHN HIGHTON
The Journal of Rheumatology Apr 2009, 36 (4) 797-800; DOI: 10.3899/jrheum.080964
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Clinical Disease Manifestations Associated With Tumor Necrosis Factor Inhibitor Nonresponse in Juvenile Spondyloarthritis
  • Clinical Meaningfulness and Improvement Thresholds of Myositis Core Set Measures: Association With Patient-Reported Outcomes
  • Phoenixin-14 as a Potential Limiting Neuropeptide for Exaggerated Inflammation in Familial Mediterranean Fever and Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis: A Comparative Study
Show more Article

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire